ADAMTS13 factor deficiency in severe COVID-19 may not be immune mediated - report from a pilot study

Ashna George; Chenna Deepika; Ganesh Mohan; Riya Srishail; Vinu Rajendran; Shamee Shastry; Jayaraj Mymbilli Balakrishnan; Shwethapriya Rao

doi:10.3233/CH-221514

ADAMTS13 factor deficiency in severe COVID-19 may not be immune mediated - report from a pilot study

Ashna George, Chenna Deepika, Ganesh Mohan, Riya Srishail, Vinu Rajendran, Shamee Shastry, Jayaraj Mymbilli Balakrishnan, Shwethapriya Rao

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

BACKGROUND: The assessment of ADAMTS13 factor activity and inhibitor levels was conducted in severe COVID-19 patients as an observational study. RESULTS: A total of 14 patients were included and the average ADAMTS13 activity level at the time of admission was 28.54±30.74% (range 1.83-86.67%) which was reduced compared to controls (88.09±14.77). Nine patients had reduced ADAMTS13 factor activity (<40%) and 77.7% among them had severe deficiency (<10% activity). ADAMTS13 inhibitor was positive (>15 IU/mL) only in two patients and an overall mean value was 8.15±5.8. Elevated D-Dimer and length of hospital stay had significant correlation with ADAMTS13 activity (-0.247 and 0.306 respectively). No features of thrombotic microangiopathy were observed and hence no plasma exchange was performed. CONCLUSION: Reduced ADAMTS13 factor activity without inhibitor development may give a clue to the disease progress in COVID-19.

Original language	English
Pages (from-to)	193-198
Number of pages	6
Journal	Clinical Hemorheology and Microcirculation
Volume	1
Issue number	1
DOIs	https://doi.org/10.3233/CH-221514
Publication status	Published - 2022

All Science Journal Classification (ASJC) codes

Physiology
Hematology
Cardiology and Cardiovascular Medicine
Physiology (medical)

Access to Document

10.3233/CH-221514

Cite this

@article{5f7a9b5f26844422b386bdc96d182fe2,

title = "ADAMTS13 factor deficiency in severe COVID-19 may not be immune mediated - report from a pilot study",

abstract = "BACKGROUND: The assessment of ADAMTS13 factor activity and inhibitor levels was conducted in severe COVID-19 patients as an observational study. RESULTS: A total of 14 patients were included and the average ADAMTS13 activity level at the time of admission was 28.54±30.74% (range 1.83-86.67%) which was reduced compared to controls (88.09±14.77). Nine patients had reduced ADAMTS13 factor activity (<40%) and 77.7% among them had severe deficiency (<10% activity). ADAMTS13 inhibitor was positive (>15 IU/mL) only in two patients and an overall mean value was 8.15±5.8. Elevated D-Dimer and length of hospital stay had significant correlation with ADAMTS13 activity (-0.247 and 0.306 respectively). No features of thrombotic microangiopathy were observed and hence no plasma exchange was performed. CONCLUSION: Reduced ADAMTS13 factor activity without inhibitor development may give a clue to the disease progress in COVID-19.",

author = "Ashna George and Chenna Deepika and Ganesh Mohan and Riya Srishail and Vinu Rajendran and Shamee Shastry and Balakrishnan, {Jayaraj Mymbilli} and Shwethapriya Rao",

note = "Publisher Copyright: {\textcopyright} 2022- IOS Press.",

year = "2022",

doi = "10.3233/CH-221514",

language = "English",

volume = "1",

pages = "193--198",

journal = "Clinical Hemorheology and Microcirculation",

issn = "1386-0291",

publisher = "IOS Press",

number = "1",

}

TY - JOUR

T1 - ADAMTS13 factor deficiency in severe COVID-19 may not be immune mediated - report from a pilot study

AU - George, Ashna

AU - Deepika, Chenna

AU - Mohan, Ganesh

AU - Srishail, Riya

AU - Rajendran, Vinu

AU - Shastry, Shamee

AU - Balakrishnan, Jayaraj Mymbilli

AU - Rao, Shwethapriya

PY - 2022

Y1 - 2022

N2 - BACKGROUND: The assessment of ADAMTS13 factor activity and inhibitor levels was conducted in severe COVID-19 patients as an observational study. RESULTS: A total of 14 patients were included and the average ADAMTS13 activity level at the time of admission was 28.54±30.74% (range 1.83-86.67%) which was reduced compared to controls (88.09±14.77). Nine patients had reduced ADAMTS13 factor activity (<40%) and 77.7% among them had severe deficiency (<10% activity). ADAMTS13 inhibitor was positive (>15 IU/mL) only in two patients and an overall mean value was 8.15±5.8. Elevated D-Dimer and length of hospital stay had significant correlation with ADAMTS13 activity (-0.247 and 0.306 respectively). No features of thrombotic microangiopathy were observed and hence no plasma exchange was performed. CONCLUSION: Reduced ADAMTS13 factor activity without inhibitor development may give a clue to the disease progress in COVID-19.

AB - BACKGROUND: The assessment of ADAMTS13 factor activity and inhibitor levels was conducted in severe COVID-19 patients as an observational study. RESULTS: A total of 14 patients were included and the average ADAMTS13 activity level at the time of admission was 28.54±30.74% (range 1.83-86.67%) which was reduced compared to controls (88.09±14.77). Nine patients had reduced ADAMTS13 factor activity (<40%) and 77.7% among them had severe deficiency (<10% activity). ADAMTS13 inhibitor was positive (>15 IU/mL) only in two patients and an overall mean value was 8.15±5.8. Elevated D-Dimer and length of hospital stay had significant correlation with ADAMTS13 activity (-0.247 and 0.306 respectively). No features of thrombotic microangiopathy were observed and hence no plasma exchange was performed. CONCLUSION: Reduced ADAMTS13 factor activity without inhibitor development may give a clue to the disease progress in COVID-19.

UR - http://www.scopus.com/inward/record.url?scp=85142403162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85142403162&partnerID=8YFLogxK

U2 - 10.3233/CH-221514

DO - 10.3233/CH-221514

M3 - Article

C2 - 35754264

AN - SCOPUS:85142403162

SN - 1386-0291

VL - 1

SP - 193

EP - 198

JO - Clinical Hemorheology and Microcirculation

JF - Clinical Hemorheology and Microcirculation

IS - 1

ER -

ADAMTS13 factor deficiency in severe COVID-19 may not be immune mediated - report from a pilot study

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this